<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133367</url>
  </required_header>
  <id_info>
    <org_study_id>05-154</org_study_id>
    <nct_id>NCT00133367</nct_id>
  </id_info>
  <brief_title>Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus</brief_title>
  <official_title>Phase II Study of Sequential Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effectiveness of 2 drugs, tacrolimus and&#xD;
      sirolimus, in preventing graft versus host disease (GVHD) after treatment with chemotherapy&#xD;
      followed by donor cord blood transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The chemotherapy portion of the study involves the intravenous administration of&#xD;
           fludarabine, for six days (Days 8, 7, 6, 5,4, and 3) before transplant, melphalan, for&#xD;
           one day (Day 2) before transplant. Antithymocyte globulin, or thymoglobulin, will be&#xD;
           given IV daily for 4 days (days 7, 5, 3, and 1 before transplant). This drug also helps&#xD;
           to suppress the immune system, allowing the cord blood cells to grow and reproduce.&#xD;
&#xD;
        -  Immunosuppression therapy consists of the drugs tacrolimus and sirolimus. The patient&#xD;
           will receive these 3 days before the transplant and every day for 3-6 months after&#xD;
           transplant. After the first 100 days post transplant, the doses of tacrolimus and&#xD;
           sirolimus will begin to be reduced with the goal of having the patient off both drugs by&#xD;
           6-9 months after transplant.&#xD;
&#xD;
        -  After completion of conditioning therapy described above, the patient will receive 2&#xD;
           cord blood units 1-6 hours apart. To help with engraftment, the patient will also&#xD;
           receive G-CSF starting on day five after transplant, until the patients white blood&#xD;
           cells recover.&#xD;
&#xD;
        -  Follow-up visits will continue every 6 months after the last treatment dose and will&#xD;
           last up to 2 years.&#xD;
&#xD;
        -  Blood tests will be drawn frequently to test whether the donor's immune cells have&#xD;
           engrafted as well as to test the levels of Tacrolimus and Sirolimus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effectiveness of tacrolimus and sirolimus in preventing graft versus host disease</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the days to neutrophil engraftment and platelet engraftment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the relapse rate and overall disease free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Myelogenous Leukemia</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Given starting on day 5 after transplant until the subjects white blood cell count recovers.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte globulin</intervention_name>
    <description>Given intravenously for 4 days before transplant (days 7, 5, 3, 1).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Given intravenously for 4 days before transplant (days 7, 5, 3, 1).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given intravenously on day 2 before transplant.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hematologic malignancies for whom allogeneic stem cell transplantation&#xD;
             is deemed clinically appropriate&#xD;
&#xD;
          -  Non-Hodgkin's lymphoma, or Hodgkin's lymphoma: in Complete Remission &gt;2 (second&#xD;
             complete remission, third complete remission, etc) or in partial remission&#xD;
&#xD;
          -  Multiple myeloma: relapsed&#xD;
&#xD;
          -  Chronic lymphocytic leukemia, Rai stage III or IV, or lymphocyte doubling time of 6&#xD;
             months, or stage I-II, having progressed after &gt; 2 chemotherapy regimens, in partial&#xD;
             remission.&#xD;
&#xD;
          -  Acute myelogenous or lymphoblastic leukemia in second or subsequent remission or in&#xD;
             first remission with adverse cytogenetic or antecedent hematologic disorder&#xD;
&#xD;
          -  Chronic myelogenous leukemia in accelerated or second stable phase, or imatinib&#xD;
             resistant and not eligible for an ablative transplant&#xD;
&#xD;
          -  Myelodysplasia, previously treated or not eligible for ablative transplant&#xD;
&#xD;
          -  Age 18-65 years.&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  Lack of 6/6 or 5/6 HLA-matched related, 10/10 matched unrelated donor, or unrelated&#xD;
             donor not available within the time frame necessary to perform a potentially curative&#xD;
             stem cell transplant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac disease:&#xD;
&#xD;
               -  symptomatic congestive heart failure or&#xD;
&#xD;
               -  radionuclide ventriculogram (RVG) or echocardiogram determined left ventricular&#xD;
                  ejection fraction of &lt; 40%,&#xD;
&#xD;
               -  active angina pectoris, or&#xD;
&#xD;
               -  uncontrolled hypertension.&#xD;
&#xD;
          -  Pulmonary disease:&#xD;
&#xD;
               -  severe chronic obstructive lung disease, or&#xD;
&#xD;
               -  symptomatic restrictive lung disease, or&#xD;
&#xD;
               -  corrected DLCO of &lt; 50% of predicted.&#xD;
&#xD;
          -  Renal disease:&#xD;
&#xD;
               -  serum creatinine &gt; 2.0 mg/dl.&#xD;
&#xD;
          -  Hepatic disease:&#xD;
&#xD;
               -  serum bilirubin &gt; 2.0 mg/dl (except in the case of Gilbert's syndrome or&#xD;
                  hemolytic anemia in which the bilirubin can be elevated greater than 2.0mg/dl),&#xD;
&#xD;
               -  SGOT or SGPT &gt; 3 x normal.&#xD;
&#xD;
          -  Neurologic disease:&#xD;
&#xD;
               -  symptomatic leukoencephalopathy,&#xD;
&#xD;
               -  active central nervous system (CNS) malignancy or other neuropsychiatric&#xD;
                  abnormalities believed to preclude transplantation (previous CNS malignancy,&#xD;
                  presently in complete remission [CR] is not exclusion).&#xD;
&#xD;
          -  HIV antibody.&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  Pregnancy or breast feeding mother.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K Ballen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Ballen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Cord blood transfusion</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

